[ad_1]
The test was performed on more than 3,300 people with pancreatic cancer, identifying about 250 people with the defective gene. One group, randomly selected, received the drug called olaparib and another group, a placebo.
It has been discovered that the olaparib, developed by MSD (Merck Sharp and Dohme) and AstroZeneca under the name "Lynparza", reduces the risk of disease progression by 47% compared to the control group.
In patients who have received olaparib, the disease was controlled almost twice as long as in patients receiving placebo.
Suzanne Cole, an oncologist at Southwestern Medical Center, who did not participate in the study, said the research represented a major breakthrough for patients with metastatic pancreatic cancer.
Kindler cited the case of a patient who lost his brother before knowing that he was suffering from the same type of cancer. It was later discovered that he was carrying the BRCA mutation and had been included in the test. "Every time we do a scan, your tumor goes down," Kindler said.
"Take the pill twice a day for two and a half years, she is still there and leads a normal life," he concludes.
[ad_2]
Source link
